News and announcements – All market releases
 |
 |
Releases open in a new window/tab – close to return to the list below
27 March 2009 – RESULT OF EXTRAORDINARY GENERAL MEETING
3rd March 2009 – Stemcells, Inc. to aquire cell-based drug discovery platforms and related businesses of Stem Cell Sciences plc for US$4.8 million
2nd March, 2009 – Stemcells, Inc. to aquire cell-based drug discovery platforms and related businesses of Stem Cell Sciences plc
5th January 2009 – Stem Cell Sciences signs further licence agreement for stem cell technology with major pharmaceutical company
29th December 2008 – Technique for creating authentic rat embryonic stem cells published in ‘Cell’
24 December 2008 – Receipt of loan funding and termination of offer period
8th December 2008 – Offer period
25th November 2008 – Suspension of trading
20th November 2008 – Stem Cell Sciences signs service agreement with Pfizer to provide access to proprietary technologies and methods
14th November 2008 – Stem Cell Sciences reinforces its international patent position in stem cell technologies
11th November 2008 – SCS licenses stem cell technology to leading provider of genetically modified models for pharmaceutical research
10th November 2008 – Stem Cell Sciences enters into services agreement with Huntington's Research Group, CHDI Foundation Inc.
24th October 2008 – Technique for rapidly reprogramming adult cells into stem cells published in PLoS Biology
8th October 2008 – Stem Cell Sciences in-licenses technology from University of Cambridge for reprogramming adult cells into stem cells
2nd September 2008 – Stem Cell Sciences announces the creation of the world’s first authentic rat embryonic stem cells from its exclusively licensed technology
28th August 2008 – SCS Half Year June 2008 Report– Download PDF
Stem Cell Sciences (AIM: STEM, ASX: STC), a company focused on
the commercialisation of stem cells and stem cell technologies, announces its half-yearly report for the six
months ended 30th June 2008.
28th August 2008 – SCS Half Year Presentation June 2008 – Download PDF
Corporate Presentation of Interim Results – Dr Alastair Riddell CEO
9.7.2008 – Stem Cell Sciences granted UK patent for new growth medium to revolutionize growth of authentic embryonic stem cells
Stem Cell Sciences plc (AIM:STEM, ASX:STC) today announced that the UK Patent Office has granted it a patent covering the Company’s new range of stem cell culture media. The new Culticell iSTEM™ range uses the inhibitor based technology discovered by Professor Austin Smith and recently published in Nature journal (vol. 453, pp.519-523).
30.6.2008 – Change of advisor
Stem Cell Sciences plc (AIM:STEM, ASX:STC), a leading provider of cells and cell culture media to the global pharmaceutical, biopharmaceutical and research markets, announced today that with immediate effect it has appointed Daniel Stewart & Company plc as its Nominated Adviser and Broker.
18.6.2008 – Stem Cell Sciences licenses-in fluorescent protein technology to enhance stemcell research tools and services offerings
Stem Cell Sciences plc (AIM:STEM, ASX:STC), a leading provider of stem cells and associated technologies for drug discovery, today announced the licensing of certain rights to green fluorescent protein (GFP) technology from Prolume Ltd (Arizona, USA).
5.6.2008 – Stem Cell Sciences granted European patent on HEScGRO™ and EScGRO™ media
Stem Cell Sciences plc (AIM:STEM, ASX:STC) today announced that the European Patent Office has granted a patent that protects its existing range of embryonic stem cell culture media. The media, marketed in Europe under the brands HEScGRO™ and EScGRO™, are used in the culture of embryonic stem cells from human and mouse, respectively.
Stem Cell Sciences plc (AIM:STEM, ASX:STC) today announced that the European Patent Office (“EPO”) has granted it a second patent for ‘Nanog’, a key factor used to convert adult cells back into a pluripotent state. With this technology, adult cells can be reprogrammed to behave like embryonic stem cells, thus avoiding the controversy associated with using embryos.
28.5.2008 – Grant of Options
Stem Cell Sciences plc, the global biotechnology company focused on the commercialisation of stem cells and stem cell technologies in research and cell-based therapies, announces that on 23rd May 2008, Dr Alastair J. Riddell, Chief Executive Officer, was granted options to acquire 680,484 new Ordinary Shares in the Company at a price of 17 pence per share.
28.5.2008 – ASX – Appendix 3Y
Change of Director's Interest Notice
22.5.2008 – Stem Cell Sciences launches novel stem media based on new understanding of ES cell self-renewal published in Nature by Prof Austin Smith
Stem Cell Sciences plc (AIM:STEM, ASX:STC) today announced the launch of Culticell iSTEM, a novel, serum-free, feeder-free embryonic stem (ES) cell research media product, that maintains cells in their basal, pluripotent state. Culticell iSTEM provides researchers with a purer starting point for investigating the biological potential of ES cells.
16.5.2008 – Results of annual general meeting 15 May 2008
Stem Cell Sciences plc (AIM:STEM, ASX:STC) today announced that all the motions put to Members were approved at the AGM on a show of hands.
14.5.2008 – Stem Cell Sciences granted broad US stem cell media patent
Stem Cell Sciences plc (AIM:STEM, ASX:STC) today announced that the US Patent and Trademark Office (“USPTO”) has granted its patent for technology that improves the efficiency of the culture and derivation of embryonic stem cells which leads to an increased purity of the cells.
30.4.2008 – ASX - Appendix 4C Quarterly Report
ASX Quarterly Report
29.4.2008 – Grant of Options
Stem Cell Sciences plc, the global biotechnology company focused on the commercialisation of stem cells and stem cell technologies in research and cell-based therapies, announces that on 25th April 2008, Dr Alastair J Riddell, Chief Executive Officer, was granted options to acquire 162,500 new Ordinary Shares in the Company at a price of 15 pence per share.
29.4.2008 – ASX - Appendix 3Y
Change of Director's Interests
29.4.2008 – Shareholder Movement
Stem Cell Sciences plc Holding(s) in Company TR-1: NOTIFICATION OF MAJOR INTERESTS IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Stem Cell Sciences plc 2. Reason for the notification (place an X inside the appropriate bracket/s) An acquisition or disposal of voting rights: (X) An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached: ( )
24.4.2008 – Shareholder Movement
Holding(s) in Company TR-1: NOTIFICATION OF MAJOR INTERESTS IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Stem Cell Sciences plc 2. Reason for the notification (place an X inside the appropriate bracket/s) An acquisition or disposal of voting rights: (X)
18.4.2008 – Notice of AGM
2007 Annual Report posted to Shareholders and Notice of AGM Stem Cell Sciences plc (SCS, AIM:STEM, ASX:STC) announces that its Annual Report and Accounts for the year ended 31 December 2007 and Notice of AGM are being posted to shareholders and will be made available on the Company's website,
9.4.2008 – Notification of Major Interests in Shares
Holding(s) in Company TR-1: NOTIFICATION OF MAJOR INTERESTS IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Stem Cell Sciences plc 2. Reason for the notification (place an X inside the appropriate bracket/s) An acquisition or disposal of voting rights: (X) An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached: ( )
25.3.2008 – AIM - Director's Dealing
Stem Cell Sciences plc (SCS, AIM:STEM, ASX:STC) announces that it received notification regarding a completed share transfer transaction on 20th March 2008. Dr Peter Mountford, a non-executive director of SCS, through Secure Sciences Pty Ltd, a company in which he is also a Director and holds a controlling interest, has transferred ordinary shares at nil consideration to the following parties:
25.3.2008 – ASX - Appendix 3Y - Change of Director's Interest Notice
Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Name of entity Stem Cell Sciences plc [London AIM; STEM, ASX; STC] ABN 121 989 599 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Dr Peter Scott Mountford Date of last notice 18 Feb
26.2.2008 – ASX - PRELIMINARY RESULTS FOR THE YEAR ENDED 31ST DECEMBER 2007
Stem Cell Sciences plc, a company focused on the commercialisation of stem cells and stem cell technologies, announced today preliminary results for the year ended 31st December 2007. Results for Announcement to the Market Financial Highlights • Revenue from ordinary activities £593,000 20% down (2006: £742,000) • Gross profit from ordinary activities £485,000 17% down (2006: £585,000) • Operating loss from ordinary activities £3.572 million 37% down
26.2.2008 – AIM - PRELIMINARY RESULTS FOR THE YEAR ENDED 31ST DECEMBER 2007
Stem Cell Sciences plc, a company focused on the commercialisation of stem cells and stem cell technologies, announced today preliminary results for the year ended 31st December 2007. Highlights • Major licensing deal with Merck & Co., Inc. for the use of novel mouse neural stem cell technology to for research use providing SCS a signing fee and milestone payments. • Signing of a diabetes contract research agreemen
18.2.2008 – Appendix 3Y - Change of Director’s Interest Notice
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Dr Peter Scott Mountford Date of last notice NA Part 1 - Change of
15.2.2008 – Implementation of Strategic Restructuring
Stem Cell Sciences plc (AIM:STEM, ASX:STC) today announced the implementation of a comprehensive restructuring programme, designed to improve financial, operational and growth performance, as well as provide a greater focus on its commercialisation efforts in the application of stem cell technologies. These initiatives are the result of a strategic review that the Board, in conjunction with the new CEO Dr Alastair Riddell, commenced in 2007.
Stem Cell Sciences plc (AIM:STEM, ASX:STC) announced today that preliminary results for the year ended 31st December 2007 will be issued on Tuesday, 26th February 2008.
4.2.2008 – Non Executive Board Change
Stem Cell Sciences plc (AIM:STEM, ASX:STC) today announced that non-executive Director Jeremy Paul Scudamore, due to the increasing work load from his other non-executive positions, has reluctantly retired from the Board of SCS effective January 31, 2008 The Board of SCS would like to thank Mr Scudamore for his considerable contribution to the company and wish him well with his new endeavours.
Stem Cell Sciences plc (SCS, AIM:STEM, ASX:STC) announces that it received notification on 17th January 2008 regarding a completed share transfer transaction. Dr Peter Mountford, Chief Technology Officer of SCS, has transferred 120,000 ordinary shares representing 0.35% of the Company’s issued share capital at nil consideration from Secure Sciences Pty Ltd, a company in which Dr Mountford is a Director and holds a controlling interest, to a third party. The transaction was initiated by Dr Mountford on 2nd November 2007. A binding commitment for the transaction was previously approved by the Bo
30.1.2008 – Stem Cell Sciences Enters Agreement with Myelin Repair Foundation
STEM CELL SCIENCES ENTERS AGREEMENT WITH MYELIN REPAIR FOUNDATION TO DEVELOP SUSTAINABLE CELL SOURCES FOR CNS DRUG DISCOVERY (“Stem Cell Sciences”, “SCS”) 30th January 2008 Stem Cell Sciences plc (AIM:STEM, ASX:STC) has entered an agreement with the Myelin Repair Foundation (MRF, Saratoga, CA) for the development of techniques that will lead to scalable and sustainable sources of uniform human brain cells for research, target validation and drug discovery assays.
24.12.2007 – SCS signs Diabetes Agreement
STEM CELL SCIENCES ENTERS INTO DIABETES R&D AGREEMENT WITH MAJOR PHARMACEUTICAL COMPANY ("Stem Cell Sciences", "SCS") 24 December 2007 Cambridge, U.K. – Stem Cell Sciences plc (AIM: STEM, ASX: STC) the global biotechnology company focused on the commercialization of stem cells and stem cell technologies in research, today announced the signing of a contract research agreement with a major biopharmaceutical company. Under the terms of the agreement Stem Cell Sciences will validate its suite of cell processing technologies for the scaled, automated production of human embryonic stem c
20.12.2007 – Clarification re Grant of Options
Stem Cell Sciences plc Clarification for Grant of Options Stem Cell Sciences plc, announces clarification for options granted to Directors on 18th December 2007: Dr Alastair J. Riddell, the newly appointed Chief Executive Officer of Stem Cell Sciences, as part of his remuneration package on joining the company, was granted options to acquire 162,500 new Ordinary Shares in the Company at a strike price of 29 pence per share. These options vest over a four year period and the strike price is based upon the average price of the three previous days trading to the grant date of 18th Dec
Stem Cell Sciences plc Grant of Options Stem Cell Sciences plc, the global biotechnology company focused on the commercialisation of stem cells and stem cell technologies in research and cell-based therapies, announces that on 18th December the following options were granted to Directors: Dr Alastair J. Riddell, Chief Executive Officer, was granted options to acquire 162,500 new Ordinary Shares in the Company at a price of 29 pence per share.
19.11.2007 – STEM CELL SCIENCES APPOINTS ALASTAIR RIDDELL AS CEO
Stem Cell Sciences plc (SCS, AIM:STEM, ASX: STC), the global biotechnology company focused on the commercialisation of stem cells and stem cell technologies in research and cell-based therapies, announces today the appointment of Dr Alastair James Riddell, aged 58, as Chief Executive Officer (CEO).
9.11.2007 – SCS regains all rights to commercialise its NS Cell Technology globally
Stem Cell Sciences plc (AIM: STEM, ASX: STC) today announces that the company has secured all outstanding rights to commercialise its neural stem (NS) cell technology for both research and stem-cell based therapies.
23.10.2007 – Stem Cell Sciences to develop novel muscle stem cells for drug discovery and toxicology
Stem Cell Sciences plc (SCS, AIM:STEM, ASX:STC), the global biotechnology company focused on the commercialisation of stem cells and stem cell technologies in research and cell-based therapies, today announced the signing of an exclusive agreement with San Raffaele Scientific Institute (Milan, Italy) covering assay validation and future commercialisation of novel human muscle stem cells for drug discovery and toxicology applications. Financial terms were not disclosed.
26.9.2007 – SCS wins EU Funding to use Stem Cells for Drug Discovery
STEM CELL SCIENCES WINS EU FUNDING TO USE STEM CELLS FOR DRUG DISCOVERY ("Stem Cell Sciences", "SCS")
Stem Cell Sciences plc (SCS, AIM:STEM, ASX:STC), the global biotechnology company focused on the commercialisation of stem cells and stem cell technologies in research and cell-based therapies, is pleased to announce interim results for the half year ending 30 June 2007.
21.8.2007 – SCS Consolidates through technology buy back
21 August 2007 Stem Cell Sciences plc, (AIM:STEM, ASX: STC) today announced the completion of a technology buy-back and rights exchange with Stem Cell Sciences KK (SCS KK, Kobe) to enable each company to pursue their core business focus on a global basis.
Stem Cell Sciences plc (SCS, AIM:STEM, ASX:STC), the global biotechnology company focused on the commercialisation of stem cells and stem cell technologies, is pleased to announce that the US Patent & Trademark Office (USPTO) has granted a broad patent covering SCS’s Stem Cell Selection technology (US Patent 7,256,041).
5.7.2007 – Grant of share options
Stem Cell Sciences plc, the global biotechnology company focused on the commercialisation of stem cells and stem cell technologies in research and cell-based therapies, announces that on 19th June 2007 four non-executive Directors of the Company were granted options over Ordinary Shares in the Company
Stem Cell Sciences is pleased to announce the exclusive in-licensing of a breakthrough technology. This is expected to significantly accelerate the application of human embryonic stem (ES) cells in both research and cell-based therapies.
24.5.2007 – AIM - Results of AGM
At the Annual General Meeting held at 8.00 am on 23 May 2007, all the resolutions contained within the Notice of Meeting were passed.
1.5.2007 – ASX - Annual Report 2006
Stem Cell Sciences plc is pleased to announce its results for year ended December 31, 2006.
1.5.2007 – ASX - Annual General Meeting
Notice that the second Annual General Meeting of the Company will be held at 8am on 23 May 2007.
16.4.2007 – Shares commence trading on the Australian Stock Exchange
Stem Cell Sciences plc (AIM: STEM, ASX: STC), the global biotechnology company focused on the commercialisation of stem cells and stem cell technologies in research and cell-based therapies, is pleased to announce that its shares have today started trading on the Australian Stock Exchange at $1.24 (£0.51+),17 cents (7 pence+) above the issue price.
3.4.2007 – AIM - Stem Cell Sciences Closes Share Offer Over Subscribed
Stem Cell Sciences plc (LSE:STEM), the global biotechnology company focused on the commercialisation of stem cells and stem cell technologies in research and cell-based therapies, is pleased to announce that it has closed its share offer ahead of plans following strong demand from investors. The offer has been heavily oversubscribed.
14.3.2007 – AIM - Proposed listing on Australian Stock Exchange
Stem Cell Sciences plc, the global biotechnology company focused on the commercialisation of stem cells and stem cell technologies in research and cell-based therapies, announces that it has lodged a Prospectus with the Australian Securities and Investments Commission...
Stem Cell Sciences plc, (LSE: AIM, 'STEM') has licensed the use of their novel mouse neural stem cell technology to Merck & Co., Inc. for research use. Financial terms were not disclosed, but include a signing fee and milestone payments.
7.2.2007 – AIM - Preliminary Results for the year ended 31 December 2006
Stem Cell Sciences plc, the global biotechnology company focused on the commercialisation of stem cells and stem cell technologies in research and novel cell-based therapies, is pleased to announce preliminary results for the year ended 31 December 2006.
Stem Cell Sciences plc (AIM: STEM), the global biotechnology company focused on the commercialisation of stem cells and stem cell technologies in research and novel cell-based therapies, is pleased to announce that it has signed a Material Transfer Agreement (“MTA”) and Option to License with AIM-listed Henderson Morley plc (AIM: HML). This agreement allows Stem Cell Sciences (SCS) to explore the use of Henderson Morley’s (HM) novel L-particles and PREPS technology (“Technology”) in the design of unique stem cell based assays.
25.1.2007 – AIM - Millipore’s HEScGRO™ Medium Advances Human Embryonic Stem Cell Research
As a direct result of an agreement between Millipore and Stem Cell Sciences, announced in October 2006, Millipore Corporation have today announced the availability of HEScGRO animal component-free medium for human embryonic stem cell research.